Fundraising Fox
MaveriX Oncology
Palo Alto, US · Founded 2015 · Delaware corporation
Find your way into MaveriX Oncology
Sign up to see every warm intro you have to MaveriX Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MaveriX Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Maverix Oncology develops conditionally activated small molecule therapeutics for cancer treatment, led by a team of oncologists and cancer scientists with experience in drug discovery and development.
Founders & leadership
SA
Steven A. EverettNamed on SEC filing
Board
RP
Rick PanicucciBoard director
Reported raises · per SEC filings
Form D private placements$2.8M disclosed across 2 rounds · 2016–2019
▶$1.8MraisedOct 2019 · 1 investors · BiotechnologyRule 506(b)
▶$1.8MraisedOct 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven A. EverettExecutive Officer, Director
- Riccardo PanicucciDirector
- Kim NearingDirector
- Norbert PrenzelDirector
- Offering amount
- $20M
- Amount sold
- $1.8M
- Finders' fees
- $180K
- Placement agents
- Katalyst Securities LLC
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1000KraisedJun 2016 · 1 investors · BiotechnologyRule 506(b)
▶$1000KraisedJun 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven A. EverettExecutive Officer, Director
- Rick PanicucciDirector
- Offering amount
- $1000K
- Amount sold
- $1000K
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
TargetedoncTargeted Oncology is a medical news and education publication for oncologists and cancer care professionals, covering clinical trial data, FDA approvals, treatment guidelines, and expert commentary across cancer types. It delivers conference coverage, podcasts, videos, and short-form content focused on precision oncology and targeted cancer therapies.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as MaveriX Oncology.
Frequently asked questions
- What does MaveriX Oncology do?
- Maverix Oncology develops conditionally activated small molecule therapeutics for cancer treatment, led by a team of oncologists and cancer scientists with experience in drug discovery and development.
- How much funding has MaveriX Oncology raised?
- MaveriX Oncology has disclosed $2.8M raised across 2 rounds.
- Where is MaveriX Oncology headquartered?
- MaveriX Oncology is headquartered in Palo Alto, US.